Heat shock proteins, cell survival and drug resistance: The mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy

被引:71
作者
Landriscina, Matteo [2 ]
Amoroso, Maria Rosaria [1 ,3 ]
Piscazzi, Annamaria [2 ]
Esposito, Franca [1 ,3 ]
机构
[1] Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy
[2] Univ Foggia, Dept Med Sci, Clin Oncol Unit, I-71100 Foggia, Italy
[3] CEINGE Biotecnol Avanzate, Naples, Italy
关键词
Ovarian carcinoma; Heat shock proteins; TRAP1; Drug resistance; Apoptosis; TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE; EGCG INHIBITS GROWTH; PHASE-III TRIAL; IN-VITRO; BREAST-CANCER; HSP90; INHIBITOR; GENE-EXPRESSION; ANTITUMOR-ACTIVITY; INTERGROUP TRIAL; SINGLE-AGENT;
D O I
10.1016/j.ygyno.2009.10.078
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Protein homeostasis is a highly complex network of molecular interactions governing the health and life span of the organism. Molecular chaperones, mainly heat shock proteins (HSP) and other stress-inducible proteins abundantly expressed in multiple compartments of the cell, are major modulators of protein homeostasis. TRAM is a mitochondrial HSP involved in protection against oxidant-induced DNA damage and apoptosis. It was recently described as a component of a mitochondrial pathway selectively up-regulated in tumor cells which antagonizes the proapoptotic activity of cyclophilin D, a mitochondrial permeability transition pore regulator, and is responsible for the maintenance of mitochondrial integrity, thus favoring cell survival. Interestingly, novel TRAP1 antagonists cause sudden collapse of mitochondrial function and selective tumor cell death, suggesting that this pathway may represent a novel molecular target to improve anticancer therapy. Preliminary data suggest that TRAP1 may be a valuable biomarker in ovarian cancers: in fact, TRAP1 levels are significantly higher in cisplatin-resistant ovarian tumors and ovarian carcinoma cell lines. Conclusions. While major advances have been made in understanding the genetics and molecular biology of cancer, given the considerable heterogeneity of ovarian cancer, the introduction of novel targeted therapies and the consequent selection of treatments based on the molecular profile of each tumor may have a major impact on the management of this malignancy and might contribute to building a new era of personalized medicine. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:177 / 182
页数:6
相关论文
共 80 条
[61]   A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies [J].
Ramalingam, Suresh S. ;
Egorin, Merrill J. ;
Ramanathan, Ramesh K. ;
Remick, Scot C. ;
Sikorski, Rachel P. ;
Lagattuta, Theodore F. ;
Chatta, Gurkamal S. ;
Friedland, David M. ;
Stoller, Ronald G. ;
Potter, Douglas M. ;
Ivy, S. Percy ;
Belani, Chandra P. .
CLINICAL CANCER RESEARCH, 2008, 14 (11) :3456-3461
[62]  
Schmitt E, 2003, CANCER RES, V63, P8233
[63]   Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo [J].
Schwock, Joerg ;
Pham, Nhu-An ;
Cao, Mary P. ;
Hedley, David W. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) :669-681
[64]   EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer [J].
Shankar, Sharmila ;
Ganapathy, Suthakar ;
Hingorani, Sunil R. ;
Srivastava, Rakesh K. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 :440-452
[65]   Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models [J].
Smith, V ;
Sausville, EA ;
Camalier, RF ;
Fiebig, HH ;
Burger, AM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) :126-137
[66]   Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer [J].
Solit, David B. ;
Ivy, S. Percy ;
Kopil, Catherine ;
Sikorski, Rachel ;
Morris, Michael J. ;
Slovin, Susan F. ;
Kelly, W. Kevin ;
DeLaCruz, Anthony ;
Curley, Tracy ;
Heller, Glenn ;
Larson, Steven ;
Schwartz, Lawrence ;
Egorin, Merrill J. ;
Rosen, Neal ;
Scher, Howard I. .
CLINICAL CANCER RESEARCH, 2007, 13 (06) :1775-1782
[67]   The combination of epigallocatechin gallate and curcumin suppresses ERα-breast cancer cell growth in vitro and in vivo [J].
Somers-Edgar, Tiffany J. ;
Scandlyn, Marissa J. ;
Stuart, Emma C. ;
Le Nedelec, Martin J. ;
Valentine, Sophie P. ;
Rosengren, Rhonda J. .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (09) :1966-1971
[68]   Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer [J].
Song, Dongweon ;
Chaerkady, Raghothama ;
Tan, Aik Choon ;
Garcia-Garcia, Elena ;
Nalli, Anuradha ;
Suarez-Gauthier, Ana ;
Lopez-Rios, Fernando ;
Zhang, Xian Feng ;
Solomon, Anna ;
Tong, Jeffrey ;
Read, Margaret ;
Fritz, Christian ;
Jimeno, Antonio ;
Pandey, Akhilesh ;
Hidalgo, Manuel .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (10) :3275-3284
[69]   Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 [J].
Sydor, Jens R. ;
Normant, Emmanuel ;
Pien, Christine S. ;
Porter, James R. ;
Ge, Jie ;
Grenier, Louis ;
Pak, Roger H. ;
Ali, Janid A. ;
Dembski, Marlene S. ;
Hudak, Jebecka ;
Patterson, Jon ;
Penders, Courtney ;
Pink, Melissa ;
Read, Margaret A. ;
Sang, Jim ;
Woodward, Caroline ;
Zhang, Yilong ;
Grayzel, David S. ;
Wright, Jim ;
Barrett, John A. ;
Palombella, Vito J. ;
Adams, Julian ;
Tong, Jeffrey K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (46) :17408-17413
[70]   Gene expression profiling predicts clinical outcome of breast cancer [J].
van't Veer, LJ ;
Dai, HY ;
van de Vijver, MJ ;
He, YDD ;
Hart, AAM ;
Mao, M ;
Peterse, HL ;
van der Kooy, K ;
Marton, MJ ;
Witteveen, AT ;
Schreiber, GJ ;
Kerkhoven, RM ;
Roberts, C ;
Linsley, PS ;
Bernards, R ;
Friend, SH .
NATURE, 2002, 415 (6871) :530-536